ArticlemBio2020
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 100 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics
Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19
Who cites it
100 citing papers in PubMed, 4 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Effects of atorvastatin on inflammatory markers, lipid profile, liver enzymes, and pulmonary function in patients with lung diseases: a systematic review and meta-analysis of randomized controlled trials.European journal of medical research · 2026Pooled it
- In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.Pharmacological reports : PR · 2021Pooled it
- The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Saudi Society of Maternal-Fetal Medicine guidance on pregnancy and coronavirus disease 2019.Saudi medical journal · 2020Guideline
- Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial.Scientific reports · 2024Trial
- Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial).BMC infectious diseases · 2022Trial
- Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.Acta bio-medica : Atenei Parmensis · 2020Trial
- Impact of prior statin use on clinical outcomes in COVID-19 patients: data from tertiary referral hospitals during COVID-19 pandemic in Italy.Journal of clinical lipidologyTrial
- Impact of in-hospital statin use on mortality in COVID-19 patients from a majority African American population.Heart & lung : the journal of critical careTrial
- Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.Frontiers in medicine · 2025Article
- Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy.Pharmacological reports : PR · 2024Review
- Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients.PLoS computational biology · 2023Article
- Multi-omics analysis reveals underlying host responses in pediatric respiratory syncytial virus pneumonia.iScience · 2023Article
- Treating COVID-19: Targeting the Host Response, Not the Virus.Life (Basel, Switzerland) · 2023Review
- Phenotypical and Functional Alteration of γδ T Lymphocytes in COVID-19 Patients: Reversal by Statins.Cells · 2022Article
- The analysis of COVID-19 in-hospital mortality: A competing risk approach or a cure model?Statistical methods in medical research · 2022Article
- The Influence of SARS-CoV-2 Infection on Lipid Metabolism-The Potential Use of Lipid-Lowering Agents in COVID-19 Management.Biomedicines · 2022Review
- Association of Statins for Primary Prevention of Cardiovascular Diseases With Hospitalization for COVID-19: A Nationwide Matched Population-Based Cohort Study.Journal of the American Heart Association · 2022Article
- Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID-19 patients.Journal of hospital medicine · 2022Article
- Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.Molecular and cellular biochemistry · 2022Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.